Meet the Experts: New MRI contrast agents in the diagnosis and staging of liver tumours

 Liver tumours
 Imaging and interventional

Stolz 2
Meet the Experts
13 April 2019 09:00 - 09:50

Questions for discussion:
  • Which is the diagnostic accuracy (sensitivity vs specificity, false negative/positive) of new MRI contrast agents in the detection of HCC?
  • How much does liver function and patient cooperation capacity affectt the diagnostic performance of new MRI contrast agents? is a patient selection needed?
  • MRI with hepatobiliary contrast agents as a screening methods for all cirrhotics or a second line exam for few selected patients?
  • There are two combined contrast media available, gadoxétic acid and Gadobenate dimeglumine (Gd-BOPTA). Which one would you choose for the diagnosis and staging of primary liver tumors, and why?
  • When you phase the differential diagnosis between HCC and ICC in a patient with a healthy liver, the findings on MRI with new contrast agents could avoid the need of the lesion biopsy?